Articles By Wayne Koberstein, Executive Editor

Heading Back Home To The Heart
Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.  Continue Reading..
  • Companies To Watch: Freya Biosciences

    Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.

  • Rescuing A Company’s Core Purpose

    When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.

  • Companies To Watch: Spruce Biosciences

    Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.

  • Companies To Watch: Nido Biosciences

    See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.

  • To America, A New Biopharma Model

    Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.

  • Companies To Watch: Ventoux Biosciences

    Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.

  • Going European — Affimed’s American CBO

    Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.

  • Ways To Face New Bio Funding & Banking Risks

    Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.

  • Companies To Watch: Kinaset Therapeutics

    Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.

  • Companies To Watch: Orca Bio

    Orca Bio is creating a new cell therapy aimed at bringing rebirth to stem-cell transplantation.

  • A Quick Transition To Late-Stage Clinical Trials

    “Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.

  • Building It All In-House

    Kriya’s firm commitment to build or bring all key functions in house may be unusual for such a young enterprise, but it has been consistent from the beginning.

  • Companies To Watch: Sonoma Biotherapeutics

    Sonoma Biotherapeutics is bioengineering T cells to create potential cures for autoimmune and inflammatory conditions.

  • Companies To Watch: KaliVir Immunotherapeutics

    KaliVir Immunotherapeutics is engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.